The progression of ankylosing spondylitis can be slowed when tumor necrosis factor (TNF) inhibitors are added to high-dose nonsteroidal anti-inflammatory drugs (NSAIDs), possibly because of a synergistic effect between the two drugs, according to new research.
“This is the first study to show a relation between these drugs, and the first long-term longitudinal cohort study looking at drug effects on progression,” said investigator Lianne Gensler, MD, director of the Ankylosing Spondylitis Clinic at the University of California, San Francisco Medical Center.
She presented the research here at the International Congress on Spondyloarthritides 2016.
All 527 patients had ankylosing spondylitis with at least 2 years of clinical and radiographic imaging follow-up. Mean follow-up was 3.67 years.
Disease progression was defined as an increase of at least 2 units on the modified Stoke Ankylosing Spondylitis Spine Score (mSASSS) over 24 months.